RxDoctor Payments DataLook up a doctor →

Badri Modi, MD

Dermatology · Duarte, CANPI 1457613986

Payments from drug & device makers

$835,773in general payments, 2019–2025

Across 541 payments — averaging $1544.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$323K
  • Regeneron Healthcare Solutions, Inc.$243K
  • Regeneron$138K
  • Sanofi$113K
  • Sun Pharmaceutical Industries Inc.$7K
  • Stemline Therapeutics Inc.$5K
  • plus $6K from 9 others
$5,780in research payments, 2019–2025

Across 34 payments — averaging $170.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$6K

What the payments were for

  • Consulting fees$54,63914%
  • Speaking & faculty fees$276,52070%
  • Travel & lodging$52,80013%
  • Food & beverage$10,0883%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$835,773 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$184,062
Medicare patients
883
Services billed
2,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErivedgeVismodegib24$264,885
Dupixent SyringeDupilumab15$86,215
OtezlaApremilast15$71,250
Acitretin28$9,398
Tacrolimus22$3,486
Clobetasol Propionate66$2,994
Triamcinolone Acetonide173$2,192
Fluorouracil25$2,137
Clindamycin Phosphate19$1,040
Tretinoin20$1,036
Fluocinolone Acetonide24$990
Metronidazole25$805
Doxycycline Hyclate32$805
Minocycline Hcl15$521
Hydrocortisone42$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$44$71,25015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.

Other dermatology in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →